Olaparib (LYNPARZA, AstraZeneca and Merck) was the first PARP inhibitor to receive FDA approval for indications in breast cancer and pancreatic cancer, and has since been approved for metastatic breast cancer in patients with germline BRCA1 or BRCA2 (gBRCA1/2) mutations. The gene discussed is PARP1; the disease is pancreatic neoplasm.